Inceptionr LLC Buys 1,714 Shares of Amgen Inc. $AMGN

Posted by Brian Himes on Jun 11th, 2026

Inceptionr LLC increased its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 124.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,095 shares of the medical research company’s stock after acquiring an additional 1,714 shares during the period. Inceptionr LLC’s holdings in Amgen were worth $1,013,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of AMGN. Norges Bank bought a new stake in Amgen in the fourth quarter worth $2,164,162,000. Capital World Investors lifted its position in Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares during the last quarter. Geode Capital Management LLC lifted its position in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares during the last quarter. Vanguard Group Inc. lifted its position in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the last quarter. Finally, National Bank of Canada FI lifted its position in Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after buying an additional 863,216 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Amgen stock opened at $337.73 on Thursday. The stock has a market cap of $182.28 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 3.46 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The firm has a 50-day moving average of $340.89 and a two-hundred day moving average of $345.53.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

More Amgen News

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on AMGN shares. Leerink Partners restated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. UBS Group lifted their target price on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Rothschild & Co Redburn lifted their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Finally, Royal Bank Of Canada boosted their target price on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $354.12.

View Our Latest Analysis on Amgen

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.85% of the stock is currently owned by company insiders.

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.